Second-Generation Antidepressants for Treating Adult Depression—An Update
Risks of Severe Adverse Events From Second-Generation Antidepressants for Adults With MDD
Evidence is insufficient to evaluate the comparative risk of suicidal thoughts and behavior. Evidence is also insufficient to evaluate the comparative risk for other rare but severe adverse effects such as seizures, cardiovascular events, hyponatremia, hepatotoxicity, and serotonin syndrome.
Keywords: severe adverse events | suicidality | seizures | cardiovascular | hyponatremia | hepatotoxicity | serotonin syndrome
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.